The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignant cells showed strong membranous and cytoplasmic immunoreactivity. Most cases of malignant gliomas, lymphomas and melanomas as well as skin and testicular cancer were weakly stained or negative.
Several cases of pancreas, colorectal, ovarian and stomach cancers along with occasional urothelial cancers showed weak to moderate cytoplasmic and membranous staining. Rare cases of breast and cervix cancers displayed moderate to strong cytoplasmic positivity. Remaining cancers were weakly stained or negative.
Moderate to strong cytoplasmic immunoreactivity was observed in cancer tissues. Additional membranous staining was exhibited in few colorectal and liver cancers.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
